

# CHL Antibioqram 2025

## Canterbury/Waitaha Antimicrobial Susceptibility Test Results for Gram-positive isolates recovered from all sites: 2025

Organism Name	Antibiotics in common use (1st line reporting)										Reserved (2nd line reporting)			Topical		
	Number tested	Ampicillin/ amoxicillin	Penicillin	Meth/Flucloxacillin	Erythromycin	Clindamycin #	Gentamicin	Nitrofurantoin <sup>d</sup>	Trimethoprim <sup>d</sup>	Trimethoprim+sulfamethoxazole	Fusidic Acid #	Tetra/Doxycycline	Ciprofloxacin #	Vancomycin #	Chloramphenicol	Mupirocin (High-Level)
<i>S. aureus</i> (not MRSA)	3716		22	100	87	88	96		95	99	96	98	97	100	99	100
MRSA	488		0	0	75	85	86			92	83	95	74	100	98	100
<i>S. epidermidis</i>	300		0	44	45	72			52	53	55	88	66	100		
<i>S. saprophyticus</i>	130	96		97				99	96	97				100		
<i>Enterococcus faecalis</i>	583	100						100					98	100		
<i>Enterococcus faecium</i>	105	20												87		
<i>Streptococcus pneumoniae</i>	242	94	91		85	86				76		82		100		
Streptococcus Grp A	144	100	100		93	93				90		83		100		

## Canterbury/Waitaha Antimicrobial Susceptibility Test Results for Gram-negative isolates recovered from all sites: 2025

Organism Name	Antibiotics in common use (1st line reporting)										Reserved (2nd line reporting)				
	Number tested	Ampicillin/ amoxicillin	Amoxicillin-Clavulanate	Cefuroxime IV	Cefalexin	Gentamicin	Nitrofurantoin <sup>d</sup>	Trimethoprim <sup>d</sup>	Trimethoprim+sulfamethoxazole	Tobramycin	Tetracycline	Ceftriaxone	Piperacillin-Tazobactam <sup>\$</sup>	Cefepime #	Meropenem #
<i>Citrobacter freundii</i> complex	73	0	0	0	0	100		98	99		67	78	97	100	96
<i>Citrobacter koseri</i>	114	0	98	99	99	99		98	99		99	100	100	100	100
<i>Enterobacter cloacae</i> complex	205	0	0	0	0	98		86	91		70	77	98	100	95

# CHL Antibiogram 2025

<i>Escherichia coli</i> (inc. 657 ESBL)	4581	50	72	84	82	91	99	77	77		86	97	91	100	83
<i>Klebsiella aerogenes</i>	55	0	0	0	0	98		94	95		80	85	93	98	95
<i>Klebsiella oxytoca</i>	235	0	88	89	83	99		92	95		89	91	98	100	98
<i>Klebsiella pneumoniae</i>	605	0	82	78	73	92		84	79		80	92	83	99	80
<i>Morganella morganii</i>	73	0	0	0	0	90	0	84	86		93	96	100	100	86
<i>Proteus mirabilis</i>	243	89	98	98	97	96	0	89	91		98	100	99	100	98
<i>Serratia marcescens</i>	92	0	0	0	0	97	0	85	93		89	90	97	100	87
<i>Pseudomonas aeruginosa</i>	560	0	0	0	0		0	0	0	99		96	92	98	94
<i>Acinetobacter baumannii</i> complex *	27	0	0	0	0	79	0	0	83					89	85
<i>Haemophilus influenzae</i>	527	51	83	75					67		99				94

## Canterbury/Waitaha Antimicrobial Susceptibility Test Results for Gram-negative isolates recovered from Urinary Tract Infections: 2025

Organism Name	Antibiotics in common use (1st line reporting)								Reserved (2nd line reporting)					
	Number tested	Ampicillin/Amoxicillin	Amoxicillin-Clavulanate	Cefalexin	Gentamicin	Nitrofurantoin <sup>d</sup>	Trimethoprim <sup>d</sup>	Trimethoprim-Sulfamethoxazole	Ceftriaxone	Piperacillin-Tazobactam <sup>§</sup>	Cefepime <sup>#</sup>	Meropenem <sup>#</sup>	Fosfomycin <sup>#</sup>	Ciprofloxacin <sup>#</sup>
<i>Citrobacter freundii</i> complex	44	0	0	0	100		100	100	68	84	100	100		100
<i>Citrobacter koseri</i>	90	0	99	99	99		98	99	99	98	100	100		100
<i>Enterobacter cloacae</i> complex	108	0	0	0	98		86	90	74	80	98	100		95
<i>Escherichia coli</i>	3607	56	74	91	94	99	77	80	95	98	97	100	94	90
<i>Klebsiella aerogenes</i>	31	0	0	0	100		94	94	77	84	100	100		94
<i>Klebsiella oxytoca</i>	151	0	90	91	99		96	96	92	93	99	100		99
<i>Klebsiella pneumoniae</i>	394	0	89	92	97		84	86	94	95	95	99		90
<i>Morganella morganii</i>	43	0	0	0	88	0	84	88	93	95	100	100		88
<i>Proteus mirabilis</i>	190	91	98	97	97	0	89	92	98	99	99	100		98
<i>Serratia marcescens</i>	46	0	0	0	100	0	85	87	89	91	98	100		85

# CHL Antibiogram 2025

\* Tested on 10- 30 isolates

<sup>a</sup> S. aureus susceptible to methicillin/flucloxacillin denotes susceptibility to ceftazolin and amoxicillin-clavulanate

<sup>b</sup> Enterococcus species are intrinsically resistant to cephalosporins

<sup>c</sup> Includes Intermediate (Susceptible, Increased Exposure) results

<sup>d</sup> Treatment of uncomplicated urinary tract infections only

# Use requires patient-specific Infectious Diseases/Clinical Microbiology approval (document in clinical notes) unless following Te Whata Kura national antimicrobial guidelines.

\$ Use requires patient-specific Infectious Diseases/Clinical Microbiology/Respiratory Specialist approval (document in clinical notes) unless following Te Whata Kura national antimicrobial guidelines.

## Colour Interpretation

≥ 90% Susceptible

70 - 89% Susceptible

< 70% Susceptible

R= Intrinsically Resistant

No data or not tested